Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...
Few things have stirred up as much commotion in either the weight loss or pharmaceutical world as Ozempic and Wegovy. There's a good reason for that — these drugs have proven to be highly ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Patients on semaglutide ( Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic ...